secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phathom Pharmaceuticals, Inc. (PHAT)
CIK:        0001783183
Form:       8-K
Filed at:   2025-10-30T23:59:59+00:00
Accession:  0001193125-25-257382
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phathom Q3 revenue $49.5M, up 25% QoQ; net loss $30M; FY guidance raised to $170-175M
--------------------------------------------------------------------------------

- Net revenue of $49.5M in Q3 2025, up 25% from Q2 and from $16.4M in Q3 2024.
- Net loss narrowed to $30.0M from $85.6M in Q3 2024; non-GAAP adjusted net loss $11.2M.
- Full-year 2025 revenue guidance raised to $170-175M; expects operating profitability in 2026.
- Over 790,000 cumulative VOQUEZNA prescriptions filled; Q3 filled prescriptions up 28% QoQ.
- Appointed Sanjeev Narula as CFO/Chief Business Officer and Nancy Phelan as SVP Marketing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783183/000119312525257382/0001193125-25-257382-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783183/000119312525257382/d68071d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-257382

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer